Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 1/20 | 0.52 |
| ▸ | BRAF | P15056 | 1/20 | 0.52 |
| ▸ | SYK | P43405 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | PLK1 | P53350 | 3/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5619503 | 0.89 | PLK1 (0.46) | BRAFPLK1KMT2AMAPTCDK2 | |
| SCHEMBL6287805 | 0.88 | PLK1 (0.45) | PLK1KMT2AMAPTCDK2PLK3 | |
| SCHEMBL6291417 | 0.88 | PLK1 (0.45) | EGFRPLK1KMT2AMAPTCDK2 | |
| SCHEMBL5619813 | 0.88 | BRAF (0.50) | BRAFEGFRKDRFYNPLK1 | |
| SCHEMBL6291820 | 0.87 | TP53 (0.45) | EGFRKDRFYNPLK1LMNA | |
| SCHEMBL5621058 | 0.87 | MAPT (0.41) | RAF1BRAFSYKPLK1LMNA | |
| SCHEMBL5619495 | 0.86 | MAPT (0.42) | RAF1BRAFPLK1LMNAKMT2A | |
| SCHEMBL5619875 | 0.86 | EGFR (0.45) | EGFRPLK1KMT2AMAPTCDK2 | |
| SCHEMBL5620937 | 0.86 | MAPT (0.43) | BRAFPLK1LMNAKMT2AMAPT | |
| SCHEMBL5620338 | 0.85 | MAPT (0.43) | BRAFKDRPLK1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202243-B2 | Substituted imidazotriazines | BAYER HEALTHCARE AG (DE) | 2007-04-10 | — | — | US | disclosed |
| US-20060166993-A1 | Substituted imidazotriazines | BAYER HEALTHCARE AG (DE) | 2006-07-27 | — | — | US | disclosed |
| EP-1599479-A1 | SUBSTITUTED IMIDAZOTRIAZINES | Bayer HealthCare AG (DE) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004005290-A1 | SUBSTITUTED IMIDAZOTRIAZINES | BAYER HEALTHCARE AG (DE) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166993-A1 | Substituted imidazotriazines | SNCA, PARK7, TPMT | RAF1 1612/4885BRAF 731/4885SYK 2060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.